S.M.1 Expected value of blinded estimators
In this section, we derive the expected value of the blinded estimators given in Section 2.2.
To begin, we observe that for equation (1), for i 1 , i 2 ∈ {1, . . . , C}, j 1 , j 2 ∈ {1, . . . , T }, and k 1 , k 2 ∈ {1, . . . , n}
as is stated in Hussey and Hughes [1] . Moreover, using the standard "." notation to indicate when a variable has been summed over, and setting S a = {(x, y) ∈ (1, . . . , a) × (1, . . . , a) : x = y}, we have Cov Ȳ ij. ,Ȳ ij. = Var Ȳ ij. ,
n 2 n(σ 2 e + σ 2 c ) + n(n − 1)σ 2 c , = 1 n σ 2 e + nσ 2 c .
A straight forward adaptation of the above also gives that Cov Ȳ .j. ,Ȳ .j. = 1 nC (σ 2 e + nσ 2 c ). Now, after time period t, we compute what we refer to asS 2 Ct−t and S 2 Ct , which are given by
Without loss of generality, we can assume that µ = 0. By definition, we know that
Furthermore, exploiting the fact that X 2
Ct − t n σ 2 e + (Ct − t)σ 2 c + τ 2 1 t X (t) 1 t − τ 2 C (1 t X (t) ) · (1 t X (t) ).
Therefore, we have
(1 t X (t) ) · (1 t X (t) ),
as given in the main part of the paper.
S.M.2 Possible blinded estimators
In our described blinded SSRE procedure, we make use of the variablesS 2 Ct−t and S 2 Ct to re-estimate σ 2 c and σ 2 e .
It is important to realise though that this is not a unique method through which these variance parameters can be re-estimated. Specifically, define
By modifying the derivations in Section S.M.1, it can be shown that in the absence of period and treatment effects, we have
Consequently, there are four logical variables that could be used to estimate σ 2 e : S 2 Ct , S 2 C ,S 2 Ct−C , andS 2 t−1 .
However, it can be shown (by adapting the calculations of the previous section) that only S 2 Ct provides an unbiased estimate of σ 2 e in the presence of non-zero period and treatment effects. Accordingly, it is the most logical variable to use to estimate the residual variance.
Things are slightly more complicated for re-estimating σ 2 c , however. For this, we have five possible variables that could be employed: S 2 1 , S 2 t ,S 2 Ct−t ,S 2 Ct−1 , andS 2 C−1 . Again, modifying our derivations from Section S.M.1, we can demonstrate that all five variables lead in general to a biased estimate of σ 2 c in the presence of a non-zero treatment effect. However, only E(S 2 t ) and E(S 2 Ct−t ) are not dependent on the value of the period effects. Thus, it is sensible in general to utilise either S 2 t orS 2 Ct−t for re-estimating the between cluster variation. Simple algebraic manipulation reveals that these estimators will in fact lead to the same value forσ 2 c . Consequently, we may use either in practice.
S.M.3 Sample size re-estimation procedures: algorithm
Here, we provide a complete point-by-point algorithm for how the blinded and unblinded re-estimation procedures should be conducted.
Firstly, our blinded SSRE procedure is as follows 1. Specify values for X, α, β, δ,σ 2 c ,σ 2 e , t, τ * , n min and n max .
2. Perform an initial sample size determination, to acquire n init , assuming σ 2 e =σ 2 e and σ 2 c =σ 2 c .
3. Conduct the trial up to the end of time period t, recruiting n init individuals per cluster per period.
ComputeS 2
Ct−t and S 2 Ct .
5.
Setσ 2 e = S 2 Ct and
Note: this is the specification ofσ 2 c when we do not assume σ 2 c = 0, as in Section S.M.8.
6. Compute the exact required per cluster per period sample size, n reest , for the rest of the trial to imply the desired operating characteristics, assuming σ 2 c =σ 2 c and σ 2 e =σ 2 e . Then, set n final as follows
7. Conduct periods t + 1, . . . , T of the trial, recruiting n final patients per cluster per period.
8. Perform a final unblinded analysis on all accumulated data using equation (1) to determine efficacy.
Additionally, our unblinded SSRE procedure is as follows 1. Specify values for X, α, β, δ,σ 2 c ,σ 2 e , t, n min and n max .
4. Fit the following model to all accumulated data using REML estimation
.
From the fitted model obtain the estimatesσ 2 c andσ 2 e . 6. Compute the exact required per cluster per period sample size, n reest , for the rest of the trial to imply the desired operating characteristics assuming σ 2 c =σ 2 c and σ 2 e =σ 2 e . Then, set n final as follows In this section, we provide figures depicting the distributions ofσ 2 c ,σ 2 e , andN , corresponding to the design scenarios discussed in Section 3.1 ( Supplementary Figures 1-6 ). From Supplementary Figures 1-2 and 4-5, we can see that the blinded and unblinded procedures provide similar distributions forσ 2 e when τ = 0 or τ = δ. The same is also true ofσ 2 c when τ = 0. However, when τ = δ, the unblinded procedure tends to under-estimate σ 2 c , and the blinded procedure over-estimate σ 2 c . This has implications that can be observed in Supplementary Figures 3 and 6, in that,N is generally similar for the blinded and unblinded procedures for τ = 0 (where the distributions for the blinded procedures are shifted up slightly compared to their unblinded counterparts), but not for τ = δ.
S.M.5 Performance for varying t
Here, we provide figures depicting the distributions ofσ 2 c ,σ 2 e , andN , corresponding to the design scenarios discussed in Section 3.2 ( Supplementary Figures 7-12 ). As noted in the main manuscript, increasing the value of t generally leads to minor improvements in the median estimates ofσ 2 c andσ 2 e , and also reduces the variance in the estimates. As can be seen from Supplementary Figures 8 and 11 , the exception to this rule is the blinded procedure when τ = δ, where increasing t can lead to increased bias in the estimates ofσ 2 c . The distributions ofN , seen in S.M.6 Performance for varying τ * Next, we provide figures depicting the distributions ofσ 2 c andN , corresponding to the design scenarios discussed in Section 3.3 ( Supplementary Figures 13-16 ). We can see that the value of τ * has a strong influence on the distribution ofσ 2 c , particularly when τ = δ. This has implications for the distribution ofN ( Supplementary   Figures 14 and 16 ). Precisely, as noted in the main manuscript, the larger values ofσ 2 c provided by the choice τ * = 0 when τ = δ tends to increaseN , which in turn increases the EP of this approach compared to taking
S.M.7 Performance for varying n min and n max
We now consider how the SSRE procedures perform for different possible combinations of n min and n max . Having already considered the case with n min = 1 and n max = 1000 in Section 3.1, we now examine the other two possible combinations of n min and n max listed in Section 2.3. As in Section 3.1, we set t = 3 and t = 5 for TDS1 and TDS2 respectively, and explore (σ 2 c ,σ 2 e ) ∈ {0.5σ 2 c , σ 2 c , 1.5σ 2 c } × {0.5σ 2 e , σ 2 e , 1.5σ 2 e }, with τ = 0 or τ = δ. For the blinded procedure, we take τ * = 0. Our results are provided in Supplementary Table 1 , which contains the ERRs,
Unblinded Blinded Supplementary Figure 1 : Distributions ofσ 2 c andσ 2 e are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = 0, using the blinded (τ * = 0) and unblinded re-estimation procedures. They are given for Trial Design Setting 1 (t = 3), for a selection of possible values for the assumed variance parameters, with n min = 1 and n max = 1000.
Unblinded Blinded Supplementary Figure 4 : Distributions ofσ 2 c andσ 2 e are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = 0, using the blinded (τ * = 0) and unblinded re-estimation procedures. They are given for Trial Design Setting 2 (t = 5), for a selection of possible values for the assumed variance parameters, with n min = 1 and n max = 1000. Figure 5 : Distributions ofσ 2 c andσ 2 e are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = δ, using the blinded (τ * = 0) and unblinded re-estimation procedures. They are given for Trial Design Setting 2 (t = 5), for a selection of possible values for the assumed variance parameters, with n min = 1 and n max = 1000. Supplementary Figure 7 : Distributions ofσ 2 c andσ 2 e are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = 0, using the blinded (τ * = 0) and unblinded re-estimation procedures. They are given for Trial Design Setting 1, for a selection of possible values for the assumed variance parameters and values for t, with n min = 1 and n max = 1000. Supplementary Figure 8 : Distributions ofσ 2 c andσ 2 e are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = δ, using the blinded (τ * = 0) and unblinded re-estimation procedures. They are given for Trial Design Setting 1 (t = 3), for a selection of possible values for the assumed variance parameters and values for t, with n min = 1 and n max = 1000. Supplementary Figure 10 : Distributions ofσ 2 c andσ 2 e are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = 0, using the blinded (τ * = 0) and unblinded re-estimation procedures. They are given for Trial Design Setting 2 (t = 5), for a selection of possible values for the assumed variance parameters and values for t, with n min = 1 and n max = 1000. Supplementary Figure 11 : Distributions ofσ 2 c andσ 2 e are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = δ, using the blinded (τ * = 0) and unblinded re-estimation procedures. They are given for Trial Design Setting 2 (t = 5), for a selection of possible values for the assumed variance parameters and values for t, with n min = 1 and n max = 1000. Figure 13 : Distributions ofσ c 2 are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = 0 and τ = δ, using the blinded (τ * = 0 and τ * = δ) re-estimation procedure. They are given for Trial Design Setting 1 (t = 3), for a selection of possible values for the assumed variance parameters, with n min = 1 and n max = 1000.
and Supplementary Table 2 , which displays the median required sample sizes. Moreover, the distributions ofN are given in Supplementary Figures 17-20 .
As would be expected, we observe that when n is only allowed to increase from its initial value (n min = n init , n max = 1000), the power of our procedures improves beyond that given in Table 1 . Of course though, examining Supplementary Table 2 , this is at a cost of increased required sample sizes.
Similarly, when n min = 1, n max = n init , the EP of the procedures remains high when the variance parameters are over-specified, with the median value ofN reducing to a preferable level. However, when the variance parameters are under-specified, allowing the value of n to only decrease following the interim analysis leads to a substantial loss of power in certain circumstances, particular in TDS1. Results are presented for scenarios with τ = 0 and τ = δ, using the blinded (τ * = 0 and τ * = δ) re-estimation procedure. They are given for Trial Design Setting 1 (t = 3), for a selection of possible values for the assumed variance parameters, with n min = 1 and n max = 1000.
S.M.8 Performance assuming σ 2 c = 0
Given that, in general, we would expect our blinded estimate of σ 2 c to be biased due to τ * = τ , it is interesting to ask how well a blinded procedure that simply assumes σ 2 c =σ 2 c = 0 in the re-estimation procedure could perform.
In this section it is this we examine.
For TDS1 (t = 3) and TDS2 (t = 5), withσ 2 e ∈ {0.5σ 2 e , σ 2 e , 1.5σ 2 e }, τ ∈ {0, δ}, n min = 1, n max = 1000, and taking τ * = 0, we examine the performance of the blinded re-estimation procedure when we setσ 2 c =σ 2 c = 0.
We contrast our findings to the results from Section 3.1, and specifically Table 1 . Our findings are presented in Supplementary Table 3 .
We can see that assuming σ 2 c = 0 leads to a large drop in power relative to even assumingσ 2 c = 0.5σ 2 c . Consequently, we would caution against assuming that between cluster variance to be zero, even what it is anticipated Figure 15 : Distributions ofσ c 2 are shown via their 25th, 50th and 75th percentiles across the replicate simulations. Results are presented for scenarios with τ = 0 and τ = δ, using the blinded (τ * = 0 and τ * = δ) re-estimation procedure. They are given for Trial Design Setting 2 (t = 5), for a selection of possible values for the assumed variance parameters, with n min = 1 and n max = 1000.
to be small. S.M.9 Performance when σ 2 c = σ 2 e As can be seen in Table 1 and Supplementary Table 1 , changing the value ofσ 2 c (or evenσ 2 e in the case of Table 1) has only a very minor effect on the performance of the re-estimation procedures when all other variables are held constant. This could be a consequence of the fact that σ 2 c σ 2 e . In practice, small values of the ICC would be common. However, it is informative to ask how well the re-estimation procedures might perform for an extremely large value of ρ. Therefore, in this section we consider the performance of the re-estimation procedures in cases where σ 2 c = σ 2 e = σ 2 , say.
Precisely, we consider scenarios in which σ 2 ∈ {0.25, 0.5, 1, 2.5, 5, 10}, (σ 2 c ,σ 2 e ) = (σ 2 ,σ 2 ) ∈ Supplementary Table 1 : Empirical type-I error rates (τ = 0) and power (τ = δ) of the blinded (τ * = 0) and unblinded re-estimation procedures are shown. Results are given for Trial Design Settings 1 (t = 3) and 2 (t = 5), for a selection of possible values for the assumed variance parameters, and two different possible combinations of n min and n max .
n min = n init , n max = 1000 n min = 1, n max = n init τ = 0 (1,1000) (n init ,1000) (1,n init ) Unblinded Blinded (0 .5 Supplementary Table 4 : Empirical type-I error rates (τ = 0) and power (τ = δ) of the blinded (τ * = 0) and unblinded re-estimation procedures are shown. Results are given for Trial Design Settings 1 (t = 3) and 2 (t = 5), for scenarios with σ 2 c = σ 2 e = σ 2 andσ 2 c =σ 2 e =σ 2 , when n min = 1 and n max = 1000.
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